XSHG600010
Market cap11bUSD
Dec 24, Last price
1.92CNY
1D
-2.56%
1Q
31.94%
Jan 2017
-4.67%
Name
Inner Mongolia BaoTou Steel Union Co Ltd
Chart & Performance
Profile
Qingdao Haier Biomedical Co., Ltd. engages in the design, manufacture, marketing, and sale of low temperature storage equipment for biomedical samples worldwide. The company offers cryo, ULT, biomedical, spark free, vaccine, and plasma freezers; laboratory, pharmacy, blood bank, and vaccine refrigerators; blood/fluid warming cabinets; backup systems; consumables; cold/freezer rooms; vaccine safety solutions; and plasma apheresis systems. It also provides health care products, such as smart mobile clinic inoculation, vaccine refrigerated vehicle, intelligent vaccine shelters, P2+ mobile nucleic acid testing vehicle, smart autonomous disinfection units, air purification sterilizers, infrared thermometer, blood pressure monitor, oxygen concentrator, biosafety screening booth, solar powered medical laboratory, mobile PCR testing laboratory, and mobile container clinics. In addition, the company offers various laboratory equipment and transport coolers. Qingdao Haier Biomedical Co., Ltd. was founded in 2005 and is based in Qingdao, China. Inner Mongolia Baotou Steel Union Co., Ltd. operates as a subsidiary of Baotou Iron and Steel (Group) Co., Ltd.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|---|
2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | 2014‑12 | |
Income | ||||||||||
Revenues | 69,051,881 -4.32% | 72,171,754 -16.26% | 86,183,146 45.42% | |||||||
Cost of revenue | 66,251,405 | 68,201,895 | 77,885,540 | |||||||
Unusual Expense (Income) | ||||||||||
NOPBT | 2,800,476 | 3,969,859 | 8,297,606 | |||||||
NOPBT Margin | 4.06% | 5.50% | 9.63% | |||||||
Operating Taxes | 390,656 | 222,074 | 522,101 | |||||||
Tax Rate | 13.95% | 5.59% | 6.29% | |||||||
NOPAT | 2,409,819 | 3,747,784 | 7,775,504 | |||||||
Net income | 515,271 | 2,866,448 333.22% | ||||||||
Dividends | (1,354,212) | (3,102) | (2,952) | |||||||
Dividend yield | 2.03% | 0.00% | 0.00% | |||||||
Proceeds from repurchase of equity | (1) | |||||||||
BB yield | 0.00% | |||||||||
Debt | ||||||||||
Debt current | 28,257,069 | 19,862,044 | 15,892,908 | |||||||
Long-term debt | 15,301,158 | 14,339,259 | 16,778,948 | |||||||
Deferred revenue | 914,248 | 373,106 | 411,357 | |||||||
Other long-term liabilities | 3,935,054 | 2,947,387 | 1,290,355 | |||||||
Net debt | 32,854,639 | 21,768,396 | 20,161,366 | |||||||
Cash flow | ||||||||||
Cash from operating activities | (1,137,061) | 2,066,858 | 10,974,430 | |||||||
CAPEX | (1,756,216) | |||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | 2,323,705 | |||||||||
FCF | (7,102,297) | 5,139,547 | 11,957,363 | |||||||
Balance | ||||||||||
Cash | 9,287,028 | 11,156,982 | 11,160,674 | |||||||
Long term investments | 1,416,560 | 1,275,925 | 1,349,816 | |||||||
Excess cash | 7,250,994 | 8,824,319 | 8,201,332 | |||||||
Stockholders' equity | 61,463,271 | 61,594,924 | 63,744,792 | |||||||
Invested Capital | 102,600,507 | 88,763,678 | 88,516,687 | |||||||
ROIC | 2.52% | 4.23% | 8.56% | |||||||
ROCE | 2.55% | 4.07% | 8.58% | |||||||
EV | ||||||||||
Common stock shares outstanding | 45,599,165 | 45,585,033 | 45,585,033 | |||||||
Price | 1.46 -23.96% | 1.92 -31.18% | 2.79 138.46% | |||||||
Market cap | 66,574,781 -23.93% | 87,523,263 -31.18% | 127,182,241 138.46% | |||||||
EV | 109,072,574 | 118,258,072 | 156,280,465 | |||||||
EBITDA | 7,363,662 | 8,219,619 | 12,546,968 | |||||||
EV/EBITDA | 14.81 | 14.39 | 12.46 | |||||||
Interest | 2,150,485 | 1,721,647 | 1,829,289 | |||||||
Interest/NOPBT | 76.79% | 43.37% | 22.05% |